Clinical TrialsThe completion of enrollment in the Phase 2b CHASE trial for KPI-012 marks a significant step forward in the development for the treatment of persistent corneal epithelial defect (PCED).
Financial PerformanceNet loss of $38.5M in 2024 was less than the estimated loss, indicating better-than-expected financial performance.
Market OpportunityThere is no FDA-approved drug with a broad indication for all underlying etiologies of PCED, indicating a substantial market opportunity for KPI-012.